Distinct DNA Methylation Patterns of Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex
Bongaarts, Anika; Mijnsbergen, Caroline; Anink, Jasper J; Jansen, Floor E; Spliet, Wim G M; den Dunnen, Wilfred F A; Coras, Roland; Blümcke, Ingmar; Paulus, Werner; Gruber, Victoria E; Scholl, Theresa; Hainfellner, Johannes A; Feucht, Martha; Kotulska, Katarzyna; Jozwiak, Sergiusz; Grajkowska, Wieslawa; Buccoliero, Anna Maria; Caporalini, Chiara; Giordano, Flavio; Genitori, Lorenzo; Söylemezoğlu, Figen; Pimentel, José; Jones, David T W; Scicluna, Brendon P; Schouten-van Meeteren, Antoinette Y N; Mühlebner, Angelika; Mills, James D; Aronica, Eleonora
(2022) Cellular and Molecular Neurobiology, volume 42, issue 8, pp. 2863 - 2892
(Article)
Abstract
Tuberous sclerosis complex (TSC) is a monogenic disorder caused by mutations in either the TSC1 or TSC2 gene, two key regulators of the mechanistic target of the rapamycin complex pathway. Phenotypically, this leads to growth and formation of hamartomas in several organs, including the brain. Subependymal giant cell astrocytomas (SEGAs)
... read more
are low-grade brain tumors commonly associated with TSC. Recently, gene expression studies provided evidence that the immune system, the MAPK pathway and extracellular matrix organization play an important role in SEGA development. However, the precise mechanisms behind the gene expression changes in SEGA are still largely unknown, providing a potential role for DNA methylation. We investigated the methylation profile of SEGAs using the Illumina Infinium HumanMethylation450 BeadChip (SEGAs n = 42, periventricular control n = 8). The SEGA methylation profile was enriched for the adaptive immune system, T cell activation, leukocyte mediated immunity, extracellular structure organization and the ERK1 & ERK2 cascade. More interestingly, we identified two subgroups in the SEGA methylation data and show that the differentially expressed genes between the two subgroups are related to the MAPK cascade and adaptive immune response. Overall, this study shows that the immune system, the MAPK pathway and extracellular matrix organization are also affected on DNA methylation level, suggesting that therapeutic intervention on DNA level could be useful for these specific pathways in SEGA. Moreover, we identified two subgroups in SEGA that seem to be driven by changes in the adaptive immune response and MAPK pathway and could potentially hold predictive information on target treatment response.
show less
Download/Full Text
Keywords: Low-grade glioma, Methylation, RNA-sequencing, SEGA, TSC, Cellular and Molecular Neuroscience, Cell Biology, Journal Article
ISSN: 0272-4340
Publisher: Springer New York
Note: Funding Information: This work was supported by KIKA (Stichting Kinderen Kankervrij; AB, AM, AS, BS, EA); Stichting AMC Foundation (EA); Stichting TSC Fonds (EA); the Austrian Science Fund (FWF, no. J3499; AM); the European Union 7th framework program: acronym EPISTOP (Grant Agreement No. 602391; FJ, VG, TS, MF, SJ, AM, JM, EA) and acronym DESIRE (Grant Agreement No. 602531; IB); the European Union’s Horizon 2020 WIDESPREAD-05-2020–Twinning, (EpiEpiNet; EA,JM), Grant Agreement no. 952455; the Polish Ministerial funds for science (years 2013–2018) for the implementation of international co-financed project (KK, SJ) and internal research project of the Children’s Memorial Health Institute No.S132/2013 (KK, SJ). Funding Information: The authors thank all supporters of the TSC brain bank (Laboratory of Molecular and Cellular Neurobiology, International Institute of Molecular and Cell Biology, Warsaw, Poland: J. Jaworski, A Tempes; The Service d’ Anatomie Pathologique, CHI de Creteil and Inserm U676, Hospital Robert Debre, Paris, France: H. Adle-Biassette; Department of Pediatrics, Division of Neuropathology and Neurochemistry, Department of Neurology, Department of Neurosurgery, Medical University Vienna, Austria: M. Feucht, T. Scholl, J. Hainfellner, T. Czech; Department of Neurology and Pathology and Molecular Medicine, Charles University, 2nd Faculty of Medicine, Motol University Hospital, Prague, Czech Republic: P. Krsek, J. Zamecnik; Department of Neuropathology, John Radcliffe Hospital, Oxford, UK: C. Kennard; Department of Anatomic Pathology Sciences, Università Sapienza, Rome, Italy: M. Antonelli, F. Giangaspero; Insitute of Neuropathology, Westfälische Wilhelms – Universität Münster, Münster, Germany: W. Paulus, M. Hasselblatt; Department of Neuropathology, University Hospital Erlangen, Erlangen, Germany: R. Coras, I. Blümcke; Bethel Epilepsy Centre, Bielefeld, Germany: T. Polster, C.G. Bien; Laboratory of Neuropathology, Department of Neurology, Hospital de Santa Maria (CHLN), Lisbon, Portugal: J. Pimentel; Department of Human Pathology and Oncology, University of Florence and Division of Neurosurgery, ‘Anna Meyer’ Pediatric Hospital, Florence, Italy: A. M. Buccoliero, F. Giordano; Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey: F. Söylemezoğlu). In this regard, we would like to acknowledge all personnel involved in sending us the material. Furthermore, the authors would like to thank Dr. Mark Nellist (Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands) and Dr. David J. Kwiatkowski, MD, PhD (Division of Experimental Medicine and Medical Oncology, Brigham and Women's Hospital, Boston, USA) for performing TSC1 /TSC2 mutation analysis. Publisher Copyright: © 2021, The Author(s).
(Peer reviewed)